Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands

Michael A. Ansonoff, Philip S. Portoghese, John Pintar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction During the past decade, substantial evidence has documented that opioid receptor heterodimers form in cell lines expressing one or more opioid receptors. More recent studies have begun to investigate whether heterodimer formation also occurs in vivo. Objectives We have used opioid receptor knockout mice to determine whether the in vivo intrathecal (i.t.) pharmacological potency of delta, kappa, and bivalent kappa/delta ligands is altered in the absence of the KOR-1 and/or DOR-1 genes. Results We observe that both NorBNI (a kappa antagonist) and KDN-21 (a kappa/delta, bivalent antagonist) specifically inhibit DPDPE but not deltorphin II i.t potency in wildtype mice but that, following mutation of KOR-1, the ability of either compound to reduce DPDPE potency is lost. In contrast, knockout of KOR-1 unexpectedly slightly reduces the potency of deltorphin II (delta2) but not DPDPE (delta1). Finally, two compounds with kappa, agonist activity, 6′-GNTI (a putative kappa/delta heterodimer selective agonist) and KDAN-18 (kappa agonist/delta antagonist bivalent ligand) show reduced potency in DOR-1 KO mice. Conclusions These results show, genetically, that bivalent ligands with kappa agonist activity require delta receptors for maximal potency in vivo, which is consistent with the presence of opioid heterodimer/oligomer complexes in vivo, and also highlight the complexity of delta drug action even when complementary pharmacologic and genetic approaches are used.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalPsychopharmacology
Volume209
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Opioid Receptors
Ligands
Mutation
delta Opioid Receptor
Knockout Mice
Opioid Analgesics
Pharmacology
Cell Line
Pharmaceutical Preparations
Genes
Ala(2)-deltorphin II

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Ansonoff, Michael A. ; Portoghese, Philip S. ; Pintar, John. / Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. In: Psychopharmacology. 2010 ; Vol. 209, No. 2. pp. 161-168.
@article{b8c0faa424ef4964843373782c8e9753,
title = "Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands",
abstract = "Introduction During the past decade, substantial evidence has documented that opioid receptor heterodimers form in cell lines expressing one or more opioid receptors. More recent studies have begun to investigate whether heterodimer formation also occurs in vivo. Objectives We have used opioid receptor knockout mice to determine whether the in vivo intrathecal (i.t.) pharmacological potency of delta, kappa, and bivalent kappa/delta ligands is altered in the absence of the KOR-1 and/or DOR-1 genes. Results We observe that both NorBNI (a kappa antagonist) and KDN-21 (a kappa/delta, bivalent antagonist) specifically inhibit DPDPE but not deltorphin II i.t potency in wildtype mice but that, following mutation of KOR-1, the ability of either compound to reduce DPDPE potency is lost. In contrast, knockout of KOR-1 unexpectedly slightly reduces the potency of deltorphin II (delta2) but not DPDPE (delta1). Finally, two compounds with kappa, agonist activity, 6′-GNTI (a putative kappa/delta heterodimer selective agonist) and KDAN-18 (kappa agonist/delta antagonist bivalent ligand) show reduced potency in DOR-1 KO mice. Conclusions These results show, genetically, that bivalent ligands with kappa agonist activity require delta receptors for maximal potency in vivo, which is consistent with the presence of opioid heterodimer/oligomer complexes in vivo, and also highlight the complexity of delta drug action even when complementary pharmacologic and genetic approaches are used.",
author = "Ansonoff, {Michael A.} and Portoghese, {Philip S.} and John Pintar",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s00213-010-1826-7",
language = "English (US)",
volume = "209",
pages = "161--168",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. / Ansonoff, Michael A.; Portoghese, Philip S.; Pintar, John.

In: Psychopharmacology, Vol. 209, No. 2, 01.04.2010, p. 161-168.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands

AU - Ansonoff, Michael A.

AU - Portoghese, Philip S.

AU - Pintar, John

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Introduction During the past decade, substantial evidence has documented that opioid receptor heterodimers form in cell lines expressing one or more opioid receptors. More recent studies have begun to investigate whether heterodimer formation also occurs in vivo. Objectives We have used opioid receptor knockout mice to determine whether the in vivo intrathecal (i.t.) pharmacological potency of delta, kappa, and bivalent kappa/delta ligands is altered in the absence of the KOR-1 and/or DOR-1 genes. Results We observe that both NorBNI (a kappa antagonist) and KDN-21 (a kappa/delta, bivalent antagonist) specifically inhibit DPDPE but not deltorphin II i.t potency in wildtype mice but that, following mutation of KOR-1, the ability of either compound to reduce DPDPE potency is lost. In contrast, knockout of KOR-1 unexpectedly slightly reduces the potency of deltorphin II (delta2) but not DPDPE (delta1). Finally, two compounds with kappa, agonist activity, 6′-GNTI (a putative kappa/delta heterodimer selective agonist) and KDAN-18 (kappa agonist/delta antagonist bivalent ligand) show reduced potency in DOR-1 KO mice. Conclusions These results show, genetically, that bivalent ligands with kappa agonist activity require delta receptors for maximal potency in vivo, which is consistent with the presence of opioid heterodimer/oligomer complexes in vivo, and also highlight the complexity of delta drug action even when complementary pharmacologic and genetic approaches are used.

AB - Introduction During the past decade, substantial evidence has documented that opioid receptor heterodimers form in cell lines expressing one or more opioid receptors. More recent studies have begun to investigate whether heterodimer formation also occurs in vivo. Objectives We have used opioid receptor knockout mice to determine whether the in vivo intrathecal (i.t.) pharmacological potency of delta, kappa, and bivalent kappa/delta ligands is altered in the absence of the KOR-1 and/or DOR-1 genes. Results We observe that both NorBNI (a kappa antagonist) and KDN-21 (a kappa/delta, bivalent antagonist) specifically inhibit DPDPE but not deltorphin II i.t potency in wildtype mice but that, following mutation of KOR-1, the ability of either compound to reduce DPDPE potency is lost. In contrast, knockout of KOR-1 unexpectedly slightly reduces the potency of deltorphin II (delta2) but not DPDPE (delta1). Finally, two compounds with kappa, agonist activity, 6′-GNTI (a putative kappa/delta heterodimer selective agonist) and KDAN-18 (kappa agonist/delta antagonist bivalent ligand) show reduced potency in DOR-1 KO mice. Conclusions These results show, genetically, that bivalent ligands with kappa agonist activity require delta receptors for maximal potency in vivo, which is consistent with the presence of opioid heterodimer/oligomer complexes in vivo, and also highlight the complexity of delta drug action even when complementary pharmacologic and genetic approaches are used.

UR - http://www.scopus.com/inward/record.url?scp=77953289773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953289773&partnerID=8YFLogxK

U2 - 10.1007/s00213-010-1826-7

DO - 10.1007/s00213-010-1826-7

M3 - Article

VL - 209

SP - 161

EP - 168

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -